<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093548</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000389221</org_study_id>
    <secondary_id>UCLA-0302008-02</secondary_id>
    <nct_id>NCT00093548</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage II, Stage IIIA, Stage IIIB, or Stage IVA Liver Cancer</brief_title>
  <official_title>A Phase I/II Trial Testing Immunization With AFP + GM-CSF Plasmid Prime And AFP Adenoviral Vector Boost In Patients With Hepatocellular Carcinoma (AFP Prime-Boost Protocol)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from DNA and a gene-modified virus may make the body build an immune&#xD;
      response to kill tumor cells. Giving booster vaccinations may make a stronger immune response&#xD;
      and prevent or delay the recurrence of liver cancer.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy&#xD;
      and to see how well it works in treating patients with stage II, stage IIIA, stage IIIB, or&#xD;
      stage IVA liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the dose-limiting toxicity and maximum tolerated dose of adjuvant vaccination&#xD;
           comprising alpha fetoprotein (AFP) plasmid DNA and sargramostim (GM-CSF) plasmid DNA&#xD;
           followed by AFP adenoviral vector boost in patients with HLA-A*0201-expressing stage&#xD;
           II-IVA hepatocellular carcinoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the optimal biological dose of this regimen, as defined by the generation of&#xD;
           AFP-specific immunity, in these patients.&#xD;
&#xD;
        -  Determine disease-free survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of alpha fetoprotein (AFP) adenoviral vector boost.&#xD;
&#xD;
      Patients receive vaccination comprising AFP plasmid DNA and sargramostim (GM-CSF) plasmid DNA&#xD;
      intramuscularly (IM) on days 1, 30, and 60 in the absence of unacceptable toxicity. Patients&#xD;
      then receive boost immunization comprising AFP adenoviral vector IM and intradermally on day&#xD;
      90.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of AFP adenoviral vector boost until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed monthly for 3 months and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alpha fetoprotein adenoviral vector vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alpha fetoprotein plasmid DNA vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of hepatocellular carcinoma&#xD;
&#xD;
               -  Stage II-IVA disease&#xD;
&#xD;
                    -  No active disease after local or regional therapy (e.g., surgical resection,&#xD;
                       radiofrequency ablation, cryoablation, or ethanol injection)&#xD;
&#xD;
          -  Serum alpha fetoprotein &gt; upper limit of normal&#xD;
&#xD;
          -  HLA-A*0201 positive by DNA subtyping&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 g/dL (transfusion independent)&#xD;
&#xD;
          -  Platelet count &gt; 50,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Child Pugh class A or B liver function&#xD;
&#xD;
          -  Hepatitis B or C viral infection allowed&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV cardiac insufficiency&#xD;
&#xD;
          -  No coronary artery disease&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other acute viral, bacterial, or fungal infection requiring therapy&#xD;
&#xD;
          -  No allergy to study agents&#xD;
&#xD;
          -  No history of opportunistic infection&#xD;
&#xD;
          -  No high serum titer of neutralizing anti-adenoviral antibodies&#xD;
&#xD;
          -  No congenital or acquired condition resulting in an inability to generate an immune&#xD;
             response&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double-method (including a barrier method)&#xD;
             contraception&#xD;
&#xD;
          -  No other condition that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 30 days since prior chemotherapy&#xD;
&#xD;
          -  No concurrent cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 30 days since prior steroid therapy&#xD;
&#xD;
          -  No concurrent steroid therapy, including corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 2 weeks since prior therapy for acute infection&#xD;
&#xD;
          -  No concurrent immunosuppressive therapy&#xD;
&#xD;
          -  No concurrent cyclosporine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoni Ribas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>October 6, 2004</study_first_submitted>
  <study_first_submitted_qc>October 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2004</study_first_posted>
  <last_update_submitted>October 3, 2012</last_update_submitted>
  <last_update_submitted_qc>October 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized resectable adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

